Arsenic trioxide
Orphan DrugFDA Approved
Description
Arsenic trioxide is an antineoplastic agent used in the treatment of acute promyelocytic leukemia. It induces apoptosis in leukemia cells.
Indications & Therapeutic Use
Adult T-cell leukemia/lymphoma
Linked Diseases:
Global Availability (3 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Arsenic trioxide
| Generic Name | Arsenic trioxide |
| Brands | 1 brand available |
| Active Ingredient | Arsenic trioxide |
| Drug Class | Adult T-cell leukemia/lymphoma |
| Manufacturer | Cephalon |
| Dosage Forms | Injection |
| Medical Code | L01XX27 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00003551 |
| Countries | 3 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations4 Validated Nodes